Patient Voices: Schizophrenia

Pin It

Characterized by paranoia, anxiety, hallucinations and delusions, schizophrenia and schizoaffective disorder, a related condition, are complicated mental illnesses that make it difficult for one to determine the difference between reality and pretend. While there are medications and therapies that can help, the effects of this condition are often far- reaching. Here, seven men and women speak about living with schizophrenia or schizoaffective disorder.

New York Times
http://www.nytimes.com/interactive/2010/09/16/health/healthguide/te_schizophrenia.

Submitted by Anna

DOL RETURN-TO-WORK TOOLKIT FOR EMPLOYEES AND EMPLOYERS

This new toolkit from the Department of Labor’s (DOL) Office of Disability Employment Policy helps employers and employees understand the return-to-work process. It provides resources to help get employees who experience an illness or injury back on the job quickly and smoothly. The employee toolkit includes information about job accommodations, preparing for a job interview, resume writing, self-employment and employment-related laws. The employer toolkit has information about strategies such as offering the opportunity to work part-time, telecommuting, modifying work duties or schedules, as well as resources that can help employers retain the talents of older workers.

http://www.dol.gov/odep/return-to-work/

Submitted by Anna

THE 10 BY 10 CAMPAIGN: A NATIONAL WELLNESS ACTION PLAN TO IMPROVE LIFE EXPECTANCY BY 10 YEARS IN 10 YEARS FOR PEOPLE WITH MENTAL ILLNESS—A REPORT OF THE 2007 NATIONAL WELLNESS SUMMIT FOR PEOPLE WITH MENTAL ILLNESS

This report reviews the current state of the field on issues related to health disparities for people with mental illnesses and includes recommended action steps to implement a campaign to promote wellness and reduce early mortality by 10 years over the next 10 years.

http://store.samhsa.gov/product/SMA10-4476

Submitted by Anna

MORE THAN $3.9 MILLION FOR STATEWIDE CONSUMER NETWORK GRANTS

SAMHSA announced the award of 19 grants totaling 1.3 million for the first year and $3.9 million for up to three years to support consumer organizations in their work to improve mental health services for persons living with serious mental illnesses.

http://www.samhsa.gov/newsroom/advisories/1010060106.aspx

Submitted by Anna

Advancing Drug Discovery for Schizophrenia

March 9 – 11, 2011
The New York Academy of Sciences
Presented by the New York Academy of Sciences
Early Bird Deadline: January 07, 2011
Poster Abstract Deadline: December 10, 2010

During the past decade there has been a marked decline in the number of novel drugs developed and approved for treatment of schizophrenia despite a significant investment in research and development by the pharmaceutical industry. The goal of this conference is to facilitate the translation of discoveries in basic neuroscience into the development of innovative pharmacological agents for the treatment of schizophrenia by convening and encouraging dialogue among clinical, translational and basic neuroscientists. Plenary sessions will include discussion of genetic and epigenetic approaches to studying schizophrenia; new molecular targets and approaches to small molecule therapeutics; and the relationship between genes, function, and clinical symptoms.

http://www.nyas.org/Events/Detail.aspx?cid=55938b51-f0d8-4d2b-aab7-de7436c96440

Submitted by Anna